This study investigated the effects of treating the inflammatory response and cerebral vasospasm after subarachnoid hemorrhage with the interleukin-1 receptor antagonist anakinra and the interleukin-6 receptor antagonist tocilizumab. The gene discussed is IL6R; the disease is subarachnoid hemorrhage.